Summary. When islets were cultured with interleukin-lfl (1 or 100 pmol/1) for 12 h in arginine-containing medium, cyclic GMP levels were increased 1.6-and 4.5-fold respectively. The arginine analogue, N-m-nitro-L-arginine methyl ester, which blocks nitric oxide formation and partially reverses inhibition of insulin secretion by 100 pmol/1 interleukin-lfl, largely, but not completely, blocked generation of cyclic GMR Treatment of islets with 100 pmol/1 interleukin-lfl for 12 h significantly decreased islet cyclic AMP generation in the absence of isobutylmethylxanthine (from 13.1 +0.7 to 9.3 + 0.8 fmol/gg islet protein), this fall was arginine-dependent and may have resulted from an effect on a cyclic AMP phosphodiesterase, since it was masked ifisobutylmethylxanthine was present. Isobutylmethylxanthine (0.4 mmol/1) reduced the inhibitory potency of interleukin-lfl in 15 h slightly but significantly from 80.5 to 59.0%. The morpholinosydnonimine SIN-l, which is a nitric oxide donor, inhibited insulin secretion, raised islet cyclic GMP and lowered cyclic AMP; its effects were similar to those of interleukin-lfl. However, 6-anilinoquinoline-5,8-quinone, [LY83583 (l-10gmol/1)], inhibited insulin secretion, and significantly decreased cyclic GMP while 8-bromocyclic GMP stimulated insulin secretion. Both low-and high-dose interleukin-lfl treatment give a large arginine-dependent and a small, yet significant, arginine-independent increase in cyclic GMR The inhibitory effect of SIN-1 or interleukin-lfl on insulin secretion seems to depend to a small extent on decreased islet cyclic AMP, though sustained increases in nitric oxide or depleted islet GTP may directly affect the secretory process. . This accounts for the considerable interest in these pro-inflammatory agents in the development of insulin-dependent diabetes mellitus. The effects of cytokines on insulin secretion [3] [4] [5] [6] [7] , DNA synthesis [8], glucose oxidation [9, 10] and cell viability are well documented [11, 12] . The mechanisms which have been investigated as triggering or mediating these events include increased prostaglandin production [11, 13] , altered activities of inositol phosphate or protein kinase C [6, 14] , inhibition of glucokinase [15] or aconitase [10] , generation of free radicals [1, 16] or activation ofproteases [7, [17] [18] [19] . These events may be accompanied by production of heatshock proteins [20, 21] , increased gene transcription [7, 22] and altered protein synthesis [23] . More recently, we have demonstrated that there is a role for L-argininederived nitric oxide in mediating part of the inhibitory effect of interleukin-lfl (IL-lfl) and in regulating the synergistic inhibition of beta cell function by combined interleukin-lfl plus TNF treatment [24] . Our results demonstrating nitric oxide generation by IL-lfl have been confirmed [10, 25] . An arginine analogue N-monomethyl-L-arginine (L-NMMA) completely reversed the inhibitory effects of IL-lfl, though the structurally different analogue N-co-nitro-L-arginine methyl ester (NAME), in our experiments, was only partially effective in attenuating inhibition [25] , despite being used in arginine-free medium.
Cytokines are known to modulate the function of the endocrine pancreas [1] . Direct inhibitory effects of interleukin-1 and -6 or combinations of intefleukins with tumour necrosis factor-o~ (TNF) or interferon-yhave been observed in insulin-secreting cells [1] , including human beta cells [2] . This accounts for the considerable interest in these pro-inflammatory agents in the development of insulin-dependent diabetes mellitus. The effects of cytokines on insulin secretion [3] [4] [5] [6] [7] , DNA synthesis [8] , glucose oxidation [9, 10] and cell viability are well documented [11, 12] . The mechanisms which have been investigated as triggering or mediating these events include increased prostaglandin production [11, 13] , altered activities of inositol phosphate or protein kinase C [6, 14] , inhibition of glucokinase [15] or aconitase [10] , generation of free radicals [1, 16] or activation ofproteases [7, [17] [18] [19] . These events may be accompanied by production of heatshock proteins [20, 21] , increased gene transcription [7, 22] and altered protein synthesis [23] . More recently, we have demonstrated that there is a role for L-argininederived nitric oxide in mediating part of the inhibitory effect of interleukin-lfl (IL-lfl) and in regulating the synergistic inhibition of beta cell function by combined interleukin-lfl plus TNF treatment [24] . Our results demonstrating nitric oxide generation by IL-lfl have been confirmed [10, 25] . An arginine analogue N-monomethyl-L-arginine (L-NMMA) completely reversed the inhibitory effects of IL-lfl, though the structurally different analogue N-co-nitro-L-arginine methyl ester (NAME), in our experiments, was only partially effective in attenuating inhibition [25] , despite being used in arginine-free medium.
Islets may also be lysed following prolonged exposure to cytokines (2-6 days) and the stages preceding lysis may be me diated rather differently than those leading to inhibition of insulin secretion (6-48 h) . Recently, nitric oxide derived from macrophages has been shown to promote islet cell lysis [26] , an effect which can be blocked by arginine analogues. We are currently investigating islet localisation of nitric oxide synthase, but wherever nitric oxide originateswhether endocrine cells [10, 24, 25] , non-endocrine islet cells [12, 26] or endothelial cells in perfused pancreas [27] its mechanism of action merits examination.
Nitric oxide is a lipophilic, short-lived free radical which reacts with haem proteins and which elevates cyclic GMP through the activation of soluble guanylate cyclase [28, 29] . The effects of IL-lfl were shown previously to be highly dose-dependent, low doses stimulated, while high doses inhibited insulin secretion [3] . In this study, we were interested in whether arginine-derived nitric oxide or nitric oxide-stimulated cyclic GMP mediates the dose-dependent effects of IL-lfl on insulin secretion or whether there was a role for altered cyclic AMP levels [17, 30] . The aims of the study were therefore: a) to resolve the question of whether cyclic GMP is a necessary mediator of the stimulatory or inhibitory effects of IL-lfl on insulin secretion; b) to see if cytokine effects could be reproduced by drug-induced elevation of nitric oxide or cyclic GMP; c) to determine whether IL-lfl affects cyclic AMP as well as cyclic GMP production in adult rat islets in culture; and d) to conduct experiments which would show whether arginine-derived nitric oxide is necessary for altered cyclic nucleotide production and changes in insulin secretion rates.
Materials and methods
Female Sprague-Dawley rats weighing 150-220g were used throughout the study; rats were fed ad libitum. Tissue culture RPMI-1640 complete medium, arginine-free RPMI or RPMI without glucose, arginine, inositol, glutamine, cysteine, methionine and leucine, but with supplements added as 100 x concentrates, were purchased from Gibco BRL (Paisley, UK). Cyclic nucleotide standards, cyclic nucleotide tyrosine methyl esters for iodination, 8-bromo cyclic GMR collagenase type XI and N-co-nitro-L-arginine methyl ester, (NAME) were from Sigma Chemicals Ltd. (Poole, Dorset, UK). ILl]3 (code 86/552) was from the National Institute for Biological Standards and Control (Potters Bar, Herts., UK). 6-anilinoquinoline-5,8-quinone, LY83583, a guanylate cyclase inhibitor was from Novabiochem (Nottingham, Notts., UK). SIN-l, a nitric oxide donor, was a gift from Dr. R. Knowles (Wellcome Research Labs, Beckenham, Kent, UK).
Preparation and culture of isolated islets of Langerhans
Islets were isolated under aseptic conditions from collagenase digested pancreases of female Sprague-Dawley rats. Typically two-three rat pancreases (for freshly isolated) or three-four pancreases (for cultured islets) were used to make two isolates per day [24] . Islets were cultured in RPMI medium containing 5.5 or 11 mmol/1 glucose, 5 % fetal calf serum, penicillin (60 U/ml) and streptomycin (100 gg/ml), for a 48-h pre-culture period. The glucose content of RPMI medium has no effect on cytokine-induced cyclic nucleotide changes. The 2-day culture was followed by a 12-15 h treatment in RPMI with and without IL-1]3. The treatment medium was either RPMI containing arginine (1 mmol/1) or arginine-free RPMI medium supplemented with NAME (1 mmol/1). In some specified experiments a low concentration of isobutylmethylxanthine (IBMX, 0.14).4mmol/1) or forskolin (5 gmol/1) was added together with the cytokine to prevent degradation of cyclic nucleotides formed or to raise cyclic AMP levels respectively. Islets were also cultured with agents which raise or lower cyclic GMP levels i.e. 8-bromo cyclic GMP (0.1-10 gmol/1) or LY83583 (1-10 gmol/1). Islets were washed free of treatment medium and were used for insulin secretion and cyclic nucleotide measurements.
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Islet incubation for insulin secretion
Cytokine -or other treated -islets were removed from culture medium and pre-incubated in Gey & Gey buffer [31] containing 2 retool/1 glucose and 1 mg/ml bovine serum albumin fraction V for 1 h. Insulin secretory responses were determined from groups of three or five islets challenged with buffer (1.0 ml) containing 2 or 20 mmol/1 glucose with and without IBMX or test compounds e.g. LY83 583 or SIN-1. At the end of a 30-min incubation, aliquots were removed for assay of insulin and, if required, acid ethanol (ethanol:concentrated HCI:H20; 23:0.45:7.0) was added in equal volume to the remaining islets and medium for extraction of insulin overnight. The extract was diluted ( x 100), and stored at -20 ~ prior to RIA. Insulin was assayed using rat insulin standard (Novo-Nordisk, Basingstoke, UK), guinea pig insulin antiserum and 125I-bovine insulin, (both antibody and label were prepared in this laboratory [321).
Cyclic GMP, cyclic AMP and protein estimation
Cytokine-treated islets were removed in groups of 15-40 to eppendoff tubes and the culture medium was removed. The islets were pre-incubated for 30 min, as for insulin secretion experiments, then incubated in buffer with and without IBMX (1.0 retool/l) for 30 min. Freshly isolated islets were pre-incubated as above and incubated with test compounds for 30 rain. In all cases the incubation medium was discarded, the islets were then boiled for 3 rain in sodium acetate buffer (50 mmol/1) pH 6.2, centrifuged at 10 000 x g for 3 min following which the supernatant was removed for RIA of cyclic nucleotides. The islet protein pellet was stored frozen, then dissolved in 0.2 ml of 0.1 mol/1 NaOH, immediately prior to assaying protein in ELISA plates using the Bradford method [33] .
Radioimmunoassay of cyclic GMP and cyclic AMP
Cyclic GMP was tested using an RIA kit (NEN-Dupont, Stevenage Herts., UK). The kit protocol was followed, except that 50 gl rather than 100 gl volumes of standard and unknown, as well as antibody and label were used. In other experiments cyclic GMP was tested by RIA using a protocol which was described originally [34] and employed in this lab previously for cyclic nucleotide measurement [35] . Identical results were obtained for cyclic GMP measurements using a purchased kit or our own assay. Antibody was prepared in this laboratory in rabbit against succinyl cyclic GMP conjugated to albumin (by Drs. Green and Ray; cross-reactivity of antibodies for other cyclic nucleotides was less than 0.1%). Cyclic GMP was used as standard and succinyl cyclic GMP tyrosyl methyl ester (TME) was iodinated in our laboratory. The labelled product was purified on paper chromatography, as previously described in detail [34] . Both kit and own assays used acetylated standards and unknowns, acetylation was performed with 2.5 gl of a mixture of triethylamine:acetic anhydride 2:1 in ethanol-washed soda glass tubes. An overnight incubation at 4~ of 50 al aliquots of sample, antibody and label was used. Bound and free label were separated using polyethylene glycol/gamma globulin max, as for the insulin assay [32] , values using this means of separation were similar to those obtained by the kit method, or by charcoal separation [35] .
Cyclic AMP was assayed using the same method as described by Brooker [34] ; antibody was a gift from Dr. M. Titheradge (Sussex University, UK), cyclic AMP standard was from Sigma Chemicals. succinyl cyclic AMP TME derivative was iodinated, as described for cyclic GME Fifty millilitres of standard or unknown was acetylated and 50 gl of both antibody and label were added to glass tubes and allowed to react overnight. Bound and free label were separated as for the cyclic GMP assay, and the cyclic nucleotide concentrations were determined using an RIA calc program on an LKB-Pharmacia multigamma counter. ) or arginine-free medium containing i retool/1 N-co-nitro-L-arginine methyl ester (NAME; ~). Groups of 15 islets were removed and processed for cyclic GMP as described in the text. Values are mean • SEM for four isolates (n = 11-14). *** p < 0.001 significantly greater than arginine control, t]] P < 0.001 significantly less than arginine control; A A/x p < 0.001 significantly greater than NAME control by Student's t-test
Statistical analysis
Data presented are usually means + SEMs. The significance of differences between means was evaluated by Student's unpaired t-test, or by one way analysis of variance. In both instances the acceptance level of significance was p < 0.05 or better.
Results
When islets are treated for 12 h, in culture, with a range of concentrations of IL-lfl and challenged afterwards for 30 rain with medium containing 20 mmol/1 glucose, the in-11 sulin secretory response ranged from stimulatory to inhibitory ( Fig. 1 a) . In islets treated with cytokine plus a low concentration of IBMX (0.1 retool/l) in a 12-h culture period, 100 pmol/1 IL-lfl treatment resulted in a 4.3-fold rise in cyclic GMP; however, alow dose (1 pmol/1) also significantly raised cyclic GMP (1.6-fold) (Fig. l b) . Cyclic GMP levels were reduced when islets were incubated in arginine-free medium containing NAME (1 mmol/1); cytokine-induced rises in cyclic GMP were significantly reduced, although a small and significant rise in cyclic GMP persisted (Fig. 1 b) . When islets were cultured in medium with 1 pmol/1 or 100 pmol/11L-lflfor 15 h and then incubated for 30 min in medium containing IBMX (1 retool/l) cyclic GMP levels were increased 3-and 8.5-fold, respectively, but there was no significant change in cyclic AMP production (Fig. 2 a) . The glucose concentration in RPMI did not alter islet cyclic nucleotide generation. When arginine was substituted by the analogue NAME, the cytokine-induced rise in cyclic GMP for 1 pmol/1 and 100 pmol/1 was 40 % and 29 %, were extracted and assayed as described in Materials and methods. Values are mean _+ SEM from four isolates (n = 10-12 for I pmol/1 treatment; n = 6 for 100 pmol/1 treatment): * p < 0.05; ** p < 0.01; 9 **p < 0.005 significantly greater than control by Student's t-test Table 1 . Effect of culture with interleukin-lfl (IL-lfl) on cyclic AMP and cyclic GMP in islets. Islets were cultured for 48 h in RPMI medium containing 5.5 mmol/1 glucose and were treated for 15 h with IL-lfl in medium containing arginine (1 mmol/1) or argininefree medium containing N-o)-nitro-L-arginine methyl ester (NAME; I mmol/1). After a pre-incubation period in buffer containing 2 retool/1 glucose, cyclic nucleotides were extracted from groups of 3040 islets and assayed as described in Materials and methods Treatment Cyclic nucleotides (fmol/gg islet protein) cyclic AMP cyclic GMP Arginine NAME Arginine NAME Control 13.1 _+0.7 (5) respectively, of that in arginine-treated islets; cyclic AMP levels were unchanged (Fig.2b) . NAME (1 mmol/1) partially reversed IL-lfl-inhibited insulin secretion [24] , but had no effect on IL-lfl-stimulated insulin secretion. The percent of stored insulin secreted in response to stimulation by 20 mmol/1 glucose was increased in islets cultured with i pmol/1 IL-lflin the presence of arginine to 2.9 from I. C. Green et al.: Interleukin-lfl and cyclic nudeotides in islets 2.1%, n = 18, p < 0.03 and in the presence of NAME to 3.3 from 2.2 %, n = 15, p < 0.03 by analysis of variance, data from three experiments performed using islet isolates from rats of different size. Although NAME significantly reduced cyclic GMP production in untreated islets by comparison with levels in islets cultured in arginine-containing media, cyclic GMP was still increased in islets which were treated with cytokines in NAME-containing media (Fig. 2 b) .
In a further series of experiments measuring combined cyclic nucleotide production, no IBMX was used in the culture or post-culture incubations. In this instance ( Table 1 ) 100 pmol/1 IL-lfl lowered cyclic AMP significantly, while raising cyclic GMP; i pmol/1 IL-lfl did not alter cyclic AMP. NAME blocked IL-1/~-induced cyclic nucleotide changes.
In order to see if the inhibitory effect of IL-lfl on glucose-induced insulin secretion could be reversed by maintaining islet cyclic AMP levels two treatments were used (Table 2) . Islets, cultured for 15 h with IL-lfl (0.1 nmol/1), were also treated with IBMX (0.4 mmol/1) or forskolin (5 gmol/1), subsequently, insulin secretory responses to glucose and IBMX (1.0 mmol/1) were measured. Longterm IBMX and forskolin treatment reduced the sensitivity of the islets to stimulation by glucose, thus altering the controls for the cytokine treatment and making interpretation less clear. The inhibitory effect of IL-lfl after 15 h in the presence of IBMX expressed as a percent of the appropriate control was altered from 19.5 +2.9% to 41 + 2.8 %; the inhibitory effect of IL-lflin the presence of forskolin was also attenuated by 20 % when the response of 20 mmol/1 glucose + IBMX was considered.
Since cyclic GMP levels are altered to the greatest extent, predictably so as a result of nitric oxide stimulation of guanylate cyclase, the role of cyclic GMP in modifying insulin secretion was investigated. The treatment of islets with 8-bromo cyclic GMP for 6 h (Fig. 3 a) or for 15 h (data not shown) resulted in stimulation of insulin secretion at a number of concentrations (0.1, 5 and 10 gmol/1). We also tested the effect of a guanylate cyclase inhibitor LY83 583 and the nitric oxide donor SIN-1 on insulin secretion (Fig. 3 b) . Insulin secretion was inhibited both by LY83 583 which lowered islet cyclic GMP (Table 3) , and by SIN 1, which raised cyclic GMP (Table 3) .
Discussion
The inhibitory effects of IL-lfl on insulin secretion are accompanied by up to nine-fold increases in islet cyclic GMR This elevation of cyclic GMP confirms that the observed increase in nitric oxide production in cultured islets leads to an anticipated stimulation of islet guanylate cyclase. The rise in cyclic GMP is greatly attenuated (to 30 % of control) if arginine is omitted from the culture medium and the arginine analogue, NAME, is substituted. This suggests that while cyclic GMP formation is largely arginine-dependent, there could be cyclic GMP generation which is arginine and nitric-oxide independent. The latter may arise from nucleotide modulation of cyclases [29] ; in IL-lfl-treated islets a possible decrease in ATP [30] LY LY SIN 1 umol/1 10,umol/l 100 Hmol/1 Fig.3a, b . Insulin secretion in response to agents which increase or decrease cyclic GMR (a) Islets were cultured for 48 h in RPMI medium containing 11 mmol/l glucose followed by culture for 6 li with and without 8-bromo-cyclic GMP at the concentrations shown. Insulin secretion by groups of three islets was determined as described in Materials and methods. Values are mean • SEM for islets from two isolates (n = 11-13): * p < 0.05 significantly different from control by Student's t-test. (b) Freshly isolated islets were pre-incubated in buffer containing 2 mmol/1 glucose for 20 rain and incubated in groups of three for 30 min in 0.6 ml buffer containing 2 mmol/1 glucose ([~]) and 20 retool/1 glucose ([]) with the additions shown. Insulin secretion was determined as described in Materials and methods. Values are the means from a minimum of four islet isolates (n = a minimum of seven where additions were made): ** p < 0.001 significantly greater than 2retool/1 glucose value; Ap<0.05; A Ap < 0.001 significantly less than 20 mmol/1 glucose value by Student's t-test. In separate experiments values for insulin secreted (fmol.islet-l.30 rain -1) in the presence of 2 mmol/1 glucose were 187 • 27 (control), 155 • 5 ( + 100 Bmol/1 SIN-l) and 123 _+ 9* (+ 10 gmol/l LY) (mean values of 15-16 determinations_+ SEM): 9 p < 0.05 significantly less than control value by Student's t-test relieve ATP inhibition of guanylate cyclase [29] . However, there are several other unknown factors which might alter the interpretation of the results obtained with arginine analogues: the efficacy of arginine analogues in inhibiting islet nitric oxide synthase as opposed to macrophage, endothelial cell or brain nitric oxide synthase is not known. In addition, some analogues have little cellular infiltration, they may inhibit arginine uptake in whole cells, rather than inhibit the enzyme nitric oxide synthase [36] . The Km of brain (constitutive) or macrophage (inducible) nitric oxide synthase for arginine is 5 and 2.8 gmol/1 respectively [37, 38] ; lowering arginine levels sufficiently to deny substrate to the enzyme, especially if islets are cultured in medium containing high levels of fetal calf serum, which contains arginine, may be difficult.
There is a poor correlation between islet cyclic GMP status and insulin secretory function [39--42] . In this study, 13 low-dose IL-lfltreatment raised cyclic GMP significantly, and under these circumstances insulin secretion was stimulated, Arginine-dependent stimulation of cyclic GMP formation, as well as of insulin secretion, has been demonstrated by others in short-term incubations in islets and RINm5F cells [40, 41] and in HIT-T15 cells [41] . In cultured islets in this study, arginine analogues have been found to lower islet cyclic GMP levels significantly; this led to decreased insulin secretion in short-term experiments with freshly isolated islets [40, 41] but decreased insulin secretion was not observed in other studies using freshly-isolated [42] or cultured islets [24] . It has also been demonstrated that when sodium nitroprusside or ascorbate are used to generate high levels of cyclic GMP that late-but not early -phase insulin secretion is inhibited in per• islets in vitro [39] . However, when we attempted to raise islet cyclic GMP with 8-bromo cyclic GMP (0.1 to 10 gmol/1) this either stimulated or had no effect on insulin secretion; we failed to demonstrate any inhibitory effect. The nitric oxide donor SIN-1 was the most effective agent at mimicking the effects of IL-lfl on insulin secretion and cyclic nucleotide generation. The time course for this effect was short (30 rain) andwe have found it difficult to induce long-term changes in cyclic GMP or insulin in 12-h culture periods with nitric oxide donors, perhaps due to the rapid effects or short half-life of the compounds we tested [43] . LY83583, a specific inhibitor of guanylate cyclase, reduced cyclic GMP levels by more than 30 %, which confirms precisely the values obtained by Laychock and colleagues [40] . We also demonstrated that it had no effect on islet cyclic AMP production. LY83 583 inhibited insulin secretion more potently than might be expected from the relatively modest reduction in cyclic GMR Its inhibitory effect, even in the presence of 2 mmol/1 glucose, suggests that it may have alternative effects on the secretory process. Thus, we have abandoned its use when designing experiments to evaluate the role of cyclic GMP in IL-lflmodulation of insulin secretion.
Conflicting results for the role of cyclic GMP in insulin secretion may be resolved by considering the intracellular mechanism by which the nucleotide levels were modified. In this study, cytokine-induced increases in cyclic GMP occur via nitric-oxide-stimulated guanylate cyclase utilising endogenous islet GTP. Cytokine-induced nitric oxide Table 3 . Effect of LY83 583 and SIN-1 on cyclic nucleotides in islets. Freshly isolated islets were pre-incubated in buffer containing 2 mmol/1 glucose for 20 rain and incubated for 30 min in groups of 30-40 in i ml buffer + LY83583 (10 gmol/l) or SIN-1 (100 btmol/1). Islet cyclic nucleotides were extracted and assayed as described in Materials and methods
Treatment
Cyclic synthase also utilises GTP in the synthesis of tetrahydrobiopterin [44] , a necessary co-factor for inducible nitric oxide synthase activity. Therefore, the net effect of cytokine induction of nitric oxide synthase may be to lower islet GTP, thus, cytokine-elevated cyclic GMP levels may indicate islet GTP levels which are rate-limiting for secretion. Depleted islet GTP has been shown to inhibit insulin secretion, possibly through impaired signal transduction [45] , or by being present in amounts which are insufficient for necessary GTP-dependent functions e. g. microtubule assembly [46] or ATP synthesis and stimulation of adenylate cyclase [47] , as shown in other cell types. GTP levels in islets have been shown to increase significantly in 30 min or less following a glucose challenge [48] , and to increase by more than 100 % in islets perifused for 150 min with medium containing 16.7 mmol/1 glucose with GDP levels unchanged [49] . Conversely, GTP synthesis was inhibited by 81% using a synthesis inhibitor, mycophenolic acid [45] , applied during an 18-20 h culture treatment. Work in our laboratory has shown that cyclic GMP formation in islets is rapid, peaking at 5-10 min, and by 30 min the levels have declined to near basal levels [35] . Since IL-lfltreatment induces nitric oxide formation from arginine, guanylate cyclase may be subjected to continuous stimulation and therefore, it is theoretically feasible that GTP levels would fall significantly and perhaps in less time than we usually allow for cytokine treatment (12-15 h). Interpretation of GTP measurements is made difficult by problems of compartmentalisation within cells and by the knowledge that GTP can be free or protein-bound. There are no reports of the effects of IL-1/3 on islet GTR Treatment of islets with a low dose of IL-lp (! pmol/1) results in a clear potentiation of insulin secretion which is accompanied by significant elevation of cyclic GMP and no change in cyclic AMR Since we have shown that this stimulation of insulin release and cyclic GMP generation occurs whether or not arginine is present, it suggests that IL-lflis acting through a signalling pathway, not involving arginine-derived nitric oxide, when it exerts low-dose stimulatory effects on secretion. However, it should be noted that under some treatment regimens significant arginine-independent rises in cyclic GMP are caused by pmol/1 amounts of IL-1/3.
Modification of the prevailing cyclic AMP 'tone' is known to affect the degree of secretagogue-induced secretion [50] . In other cell types interleukin-1 is known to stimulate cyclic AMP production [51] . However, we have not been able to demonstrate under any conditions that cyclic AMP levels are increased in IL-lfl-treated islets. We have demonstrated that cyclic AMP is not changed significantly by IL-lfl when cyclic AMP and cyclic GMP phosphodiesterases are inhibited by IBMX. This further suggests that adenylate cyclase activity in islets is unchanged by IL-1/3 treatment. More importantly, our results support the hypothesis that increased cyclic GMP is accelerating breakdown of cyclic AMP in IL-lfl-treated islets; a fall which does not occur when IBMX is used. Our results confirm observations of a decrease in cyclic AMP in IL-lfl-treated adult rat islets [30] or fetal rat islets [17] . Since adenylate cyclase would appear to be unaffected by IL-1/3, pertussis toxin alone may not reverse the effects of I. C. Green et aI.: Interleukin-1]3 and cyclic nucleotides in islets IL-1/3 as found in both fetal [17] and adult rat islets [23] especially if phosphodiesterase activity is increased [52] . This is supported by the finding that pertussis toxin combined with IL-1/3 treatment of fetal islets generated levels of cyclic AMP which were only equivalent to those in untreated islets, not pertussis toxin-treated control islets [17] . One could speculate that the phenomenon of lack of stimulation of insulin secretion by 1 gmol/1 8-bromo cyclic GMP may result if intra-islet concentrations of cyclic GMP reached a concentration range representing the gd for the cyclic GMP-stimulated phosphodiesterase which accelerates cyclic AMP degradation, which in other cell types is 2 gmol/1 [53] . However, cyclic AMP may make some contribution to the effects of IL-lfl as stimulation of beta-cell secretory activity usually accelerates cytokine effects, but not when cyclic AMP is elevated [5] . Thus, culture of islets with IL-lfl and IBMX or glucagon did not sensitise islets to the effects of IL-1/3 [5] , while secretagogues such as tolbutamide, which have been reported to increase nitric oxide formation in islets, by constitutive nitric oxide synthase [41] , accentuated cytokine inhibition of insulin secretion. If the HIT cell response is analagous to that of islets, it has been shown that a short-term (90-min) exposure to forskolin or glibenclamide is not sufficient to reverse inhibition by IL-1/3 [54] . Interpretation of our experiments using long-term treatment with IBMX for forskolin to attenuate the inhibitory effects of IL-lfl are hampered by the changes these agents induce in the control islets; however, when cytokine inhibition is expressed as a percent of the appropriate control value, then raising cyclic AMP may have a small beneficial effect. The role of cyclic nucleotide phosphodiesterases in dictating a decrease in cyclic AMP when cyclic GMP levels are highly elevated has been shown in adrenal cells [52] and their possible role in cytokine inhibition of insulin secretion requires further analysis. To date, only a type 3, cyclic GMP-inhibitable phosphodiesterase and a less well-characterised type 4 phosphodiesterase have been shown to exist in rat islets [55] . The cyclic GMPstimulated diesterase which could be involved in lowering islet cyclic AMP here is designated type 2 in other sytems [52, 56] .
Low-dose IL-lfl stimulation of insulin secretion is independent of arginine-related nitric oxide stimulation of guanylate cyclase. Stimulation by high-dose IL-lfl of nitric oxide production in islets [24, 25] leads to an anticipated stimulation of guanylate cyclase, demonstrated in our preliminary report [57] , and confirmed in RINmSF cells [58] . This phenomenon is reproduced here by a nitric oxide donor compound, SIN-1 and results in greatly increased cyclic GMP and lowered cyclic AMR However, cyclic GMP-independent effects of IL-lfl-induced nitric oxide may also be very important. Inhibition of insulin secretion by IL-lfl has consistently been associated with decreased glucose oxidation, especially at the mitochondrial level [9, 10] . It is therefore relevant for inhibition of islet function and consistent with a role for nitric oxide in the effects of IL-lfl that protein nitrosylation has been shown to occur in islets [25] , and mitochondrial enzymes may be the targets [10] . Whether or not cytokines generate rate-limiting decreases in GTP levels in islets has not been investigated.
